Septerna, Inc. (NASDAQ:SEPN – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Tuesday . Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research report on Friday, July 17th. Insiders have sold a total of 44,494 shares of company stock worth $1,469,391 over the last 90 days. Institutional Trading of SepternaSeveral hedge funds and other institutional investors have recently bought and sold shares of the company. Septerna Company Profile(Get Free Report)We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™.